BRYNN KANNE: Open Payments
NPI 1437911005 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$251 in 14 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $80 · 2025 $251
Food & beverage: $251
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 4 | $84 |
| Lilly USA, LLC | 3 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $28 |
| ABBVIE INC. | 1 | $27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
Products named: GEMTESA, MOUNJARO, Kerendia, QULIPTA, JARDIANCE, SPRAVATO, XIFAXAN, REXULTI.
Industry payments across NE — which companies pay providers there.
